IDH1 and astrocytoma (excluding glioblastoma): Patients in Class B showed significantly longer survival when compared to Class A. It is worth mentioning, however, that these findings are certainly confounded by the inclusion in Class B of astrocytomas IDH‐mutant CNS WHO grade 4 samples, which are known to have longer survival than IDH‐wildtype glioblastomas.